Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Advancing Next Generation Engineering, Clinical Strategy & Scale-Up Innovations to Further Accelerate the Next Wave of TIL Therapies to Market
Following the watershed approval of Iovance’s Lifileucel, TIL therapies are now the major therapeutic avenue for solid tumor treatment.
Happening in Boston, the 6th Annual TIL Therapies Summit was the only meeting uniting the top players in TIL all in one room to unveil:
- The latest clinical data on TIL efficacy for indications beyond melanoma
- Next generation approaches for enhanced persistence and potency
- Manufacturing innovations to scale TILs
- TIL potency assay characterization for swift regulatory approval
- And more!
Reacting to the explosive momentum within this field, the summit included more content, in our 2 tracked agenda, pre-clinical and translation and clinical strategy and manufacturing, to cover the A-Z of TIL development.
WANT TO KNOW WHO ATTENDED IN 2024? VIEW OUR BLIND ATTENDEE LIST
Our Expert Speaker Faculty Includes:
Snapshot of the 2024 Event
80+
Attendees
30+
Speakers
12
New Speaking Companies
6+
Hours of Networking
BRAND NEW
Preclinical Development & Translation, and Clinical Strategy & Manufacturing Tracks
3
Conference Days
2
Deep-Dive Interactive Workshops
2024 Partners:
